Manuscripts in Preparation
How can cancer risk communication result in protection motivation and behaviour change?
C. Riedinger, W.A.P. Klein and J. Usher-Smith.
Intended Journal: J. of Behavioural Medicine
Peer-reviewed Publications
Analysis of the components of cancer risk perception and links with intention and behaviour: A UK-based study
C. Riedinger, J. Campbell, W.M.P. Klein, R.A. Ferrer and J.A. Usher-Smith
PLoS One, 2022 Jan 13; 17(1):e0262197. DOI: 10.1371/journal.pone.0262197
Structure-based design of potent and orally active isoindolinone inhibitors of the MDM2-p53 protein-protein interaction
G. Chessari, I.R. Hardcastle, J.S. Ahn, B. Anil, E. Anscombe, R.H. Bahn, L.D. Bevan, T.J. Blackburn, I.Buck, C. Cano, B. Carbain, J. Castro, B. Cons, S.J. Cully, J.A. Endicott, L. Fazal, B.T. Golding, R.J. Griffin, K. Haggerty, S.J. Harnor, K.Hearn, S. Hobson, R.S. Holvey, S. Howard, C.E. Jennings, C.N. Johnson, J. Lunec, D.C. Miller, D.R. Newell, M.E.M. Noble, Judith Reeks, C.H. Revill, C. Riedinger, J.D. St. Denis, E. Tamanini, H. Thomas, N.TN. Thompson, M.Vinkovic, S.R. Wedge, P.A. Williams, N.E. Wilsher, B. Zhang and Y. Zhao.
J. Med. Chem., 2021; 64: 4071-4088. DOI: 10.1021/acs.jmedchem.0c02188
The Impact of Information about Different Absolute Benefits and Harms on Intention to Participate in Colorectal Cancer Screening: A Think-aloud Study and Online Randomised Experiment.
J.A. Usher-Smith, K.M. Mills, C. Riedinger, C. L. Saunders, L.M. Helsingen, L. Lytvyn, M. Buskermolen, I. Lansdorp-Vogelaar, M. Bretthauer, G. Guyatt and S.J. Griffin. PLoS One, 2021, 16(2):e0246991. DOI: 10.1371/journal.pone.0246991
The structure of an MDM2/Nutlin-3a complex, solved by use of a validated MDM2 surface entropy reduction mutant.
B. Anil, C. Riedinger, J. A. Endicott and M. E. Noble. Acta Crystallogr. D, 2013, 69(Pt 8):1358-66. DOI: 10.1107/S0907444913004459DOI: 10.1042/BJ20120542
Structural and functional characterisation of Rpn12 identifies residues required for Rpn10 proteasome incorporation.
C. Riedinger, J. Boehringer, K. Paraskevopoulos, E.D. Lowe, C. Khoudian, D. Smith, M.E. Noble and J. A. Endicott. Biochem. J., 2012, 448 (1) DOI: 10.1042/BJ20120542
MDM2-p53 protein-protein interaction inhibitors: A-ring substituted isoindolinones.
Watson, J. Liu, K. Bennaceur, C. Drummond, J. A. Endicott,B. T. Golding, R. J. Griffin, K. Haggerty, X. Lu, J. M. McDonnell, D. R. Newell, M. E. Noble, C. H. Revill , C. Riedinger, Q. Xu, Y. Zhao, J. Lunec, and I. R. Hardcastle. Bioorg. Med. Chem. Lett., 2011, 21 (19) DOI: 10.1016/j.bmcl.2011.07.084
Isoindolinone Inhibitors of the Murine Double Minute 2 (MDM2)-p53 Protein-Protein Interaction: Structure-Activity Studies Leading to Improved Potency.
R. Hardcastle, J. Lui, A. Watson, S.U. Ahmed, T.J. Blackburn, K. Bennaceur, W. Clegg, C. Drummond, J.A. Endicott, B.T. Golding, R.J. Griffin, J. Gruber, K. Haggerty, R.W. Harrington, C. Hutton, S. Kemp, J.M. McDonnell, D.R. Newell, M.E. Noble, S.L. Payne, C.H. Revill, C. Riedinger, Q. Xu, J. Lunec. J. Med. Chem., 2011, 54 (5). DOI: 10.1021/jm1011929
Understanding Small-Molecule Binding to MDM2: Insights to Structural Effects of Isoindolinone Inhibitors from NMR
C.Riedinger, M.E. Noble, D.J. Wright, F. Mulks, I.R. Hardcastle, J.A. Endicott and J.M. McDonnell
Chem. Biol. Drug Design, 2011, 77 (5). DOI: 10.1111/j.1747-0285.2011.01091.x
Structure of Rpn10 and its interactions with polyubiquitin chains and the proteasome subunit Rpn12.
C. Riedinger, J. Böhringer, J.-F. Trempe, E. Lowe, N.R. Brown, K. Gehring, M. E. M. Noble, C. Gordon and J. A. Endicott. J. Biol. Chem., 2010, 285 (44). DOI: 10.1074/jbc.M110.134510
Inhibitors of MDM2 and MDMX: a structural perspective.
C. Riedinger and J.M. McDonnell. Future Medicinal Chemistry, 2009, 1 (6). DOI: 10.4155/fmc.09.75
All change: protein conformation and the ubiquitination reaction cascade.
C. Riedinger and J.A. Endicott. F1000 Biology Reports, 2009, 19 (1). DOI: 10.3410:B1-19
Analysis of Chemical Shift Changes Reveals the Binding Modes of Isoindolinone Inhibitors of the MDM2-p53 Interaction
C. Riedinger, J.A. Endicott, S.J. Kemp, L.A. Smyth, A. Watson, E. Valeur, B.T. Golding, R.J.Griffin, I.R. Hardcastle, M.E. Noble and J.M. McDonnell. J. Am. Chem. Soc., 2008, 130 (47) DOI: 10.1021/ja8062088
Patents
New therapeutic targets: Isoindolinone inhibitors of MDM2/p53
B.T. Golding, C. Riedinger, I.R. Hardcastle, E. Valeur, A.F. Watson, M. Noble
Patent Number: GB0811643.6, Applicant: Cancer Research Technology Limited
Date filed: 25 June 2008, date published: 25 December 2009 – note: this patent has also been filed in the US